The Helsana Group is the leading health and accident insurer in Switzerland. It offers individuals and companies a complete health and prevention service in the event of sickness and accidents.
Greater transparency in the supply of medicinal products
Published in 2014, the first Helsana Drug Report was very well received by experts and the media. Like the 2014 edition, the published 2015 and 2016 reports discuss possibilities for improving the medical care of persons insured by our company.
The Swiss healthcare system is characterised by a high level of innovation. This includes new and further developments in the pharmaceutical industry. However, this also results in higher medication costs, which reached an all-time high of CHF 6.6 billion in 2015.
The Drug Report is intended to contribute to a better understanding of the Swiss medication market and the trends for quantities and costs over recent years. At the same time, we want to spark a debate on the supply of medicinal products.
Unique in Switzerland
The Helsana Drug Report is unique in Switzerland. The report – compiled in cooperation with the University Hospital of Basel (USB) and the European Centre of Pharmaceutical Medicine (ECPM) at the University of Basel – provides authentic insights into the supply of medicinal products in Switzerland. We also cast a critical eye on the market for medicinal products, look for anomalies and differences, and identify room for improvement. We do so from the perspective of our customers and in our role as the "trustee" of Swiss premium payers.
Transparency takes centre stage
The report contains assessments of market trends based on our own (anonymised) statement data and provides a representative picture of the number of recipients of medication and the resulting costs. We also provide an in-depth analysis of selected indications and medication groups. The focus falls on the transparent representation of real trends.